Compile Data Set for Download or QSAR
maximum 50k data
Found 966 of ic50 for UniProtKB: P00747
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50120225(2-{[2-(4-Guanidino-butyrylamino)-3-(4-nitro-phenyl...)
Affinity DataIC50:  0.230nMAssay Description:Concentration of the compound required to inhibit Plasmin was determinedMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514073(CHEMBL4576519)
Affinity DataIC50:  0.320nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514076(CHEMBL4456691)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514062(CHEMBL4436082)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514063(CHEMBL4447001)
Affinity DataIC50:  0.420nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514065(CHEMBL4570952)
Affinity DataIC50:  0.800nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514079(CHEMBL4449958)
Affinity DataIC50:  0.870nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514077(CHEMBL4475211)
Affinity DataIC50:  1nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514078(CHEMBL4582882)
Affinity DataIC50:  2.10nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM652813(3-chloro-N-((2-((1-methylpiperidin-4-yl)methoxy)py...)
Affinity DataIC50:  3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM652497(N-((6-(((1-methylpiperidin-4-yl)methyl)amino)pyrid...)
Affinity DataIC50:  3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM652723((S*)-4-chloro-N6-((2-((5,6,7,8-tetrahydroimidazo[1...)
Affinity DataIC50:  3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM652421(6-N-({6-[(1-methylpiperidin-4-yl)oxy]pyridin-3-yl}...)
Affinity DataIC50:  3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM652422(5-N-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}methyl...)
Affinity DataIC50:  3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM652473(5-N-[(6-{5H,6H,8H-imidazo[1,2-a]piperazin-7-yl}pyr...)
Affinity DataIC50:  3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM652731((S*)-N5-((2-((2-methyl-5,6,7,8-tetrahydroimidazo[1...)
Affinity DataIC50:  3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM652632(5-N-[(2-fluoro-4-{2-[(15,4S)-5-isopropyl-2,5-diaza...)
Affinity DataIC50:  3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM652645(N6-((2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)m...)
Affinity DataIC50:  3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM652648(N-({2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-y...)
Affinity DataIC50:  3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM652654(4-chloro-6-N-({2-[(1-methylpiperidin-4-yl)methoxy]...)
Affinity DataIC50:  3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM652657(6-N-({2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4...)
Affinity DataIC50:  3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM652689(4-fluoro-5-N-[(2-{5H,6H,7H,8H-imidazo[1,2-a]pyridi...)
Affinity DataIC50:  3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM652722(4-chloro-6-N-[(2-{5H,6H,8H-imidazo[1,2-a]pyrazin-7...)
Affinity DataIC50:  3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514075(CHEMBL4541084)
Affinity DataIC50:  8.60nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50029498(1N-[2-{2-[4-amino(imino)methylamino-1-formyl-(1S)-...)
Affinity DataIC50:  9.60nMAssay Description:In vitro Enzyme Inhibitory activity measured against PlasminMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50591422(CHEMBL5175689)
Affinity DataIC50: >10nMAssay Description:Inhibition of plasmin (unknown origin)More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290292(2-Oxo-4-(piperidin-4-yl)-1,2-dihydropyrimido[1,2-b...)
Affinity DataIC50:  10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50124990(CHEMBL355376 | N-[4-Guanidino-1-(thiazole-2-carbon...)
Affinity DataIC50:  10nMAssay Description:Inhibitory activity against PlasminMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290292(2-Oxo-4-(piperidin-4-yl)-1,2-dihydropyrimido[1,2-b...)
Affinity DataIC50:  10nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290336(10-Chloro-8-methyl-4-(piperidin-4-yl)pyrimido[1,2-...)
Affinity DataIC50:  11nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290336(10-Chloro-8-methyl-4-(piperidin-4-yl)pyrimido[1,2-...)
Affinity DataIC50:  11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290334(9-Fluoro-10-phenyl-4-(piperidin-4-yl)pyrimido[1,2-...)
Affinity DataIC50:  11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290334(9-Fluoro-10-phenyl-4-(piperidin-4-yl)pyrimido[1,2-...)
Affinity DataIC50:  11nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290324(4-(Piperidin-4-yl)-10-[2-(trifluoromethyl)phenyl]p...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290314(10-(2-Fluorophenyl)-4-(piperidin-4-yl)pyrimido[1,2...)
Affinity DataIC50:  13nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290314(10-(2-Fluorophenyl)-4-(piperidin-4-yl)pyrimido[1,2...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290309((−)-trans-10-Ethoxy-4-(2-methylpiperidin-4-y...)
Affinity DataIC50:  13nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290286(7-Bromo-4-(piperidin-4-yl)pyrido[4′,3′...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290320(10-Cyclopentyl-4-(piperidin-4-yl)pyrimido[1,2-b]in...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290324(4-(Piperidin-4-yl)-10-[2-(trifluoromethyl)phenyl]p...)
Affinity DataIC50:  13nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290286(7-Bromo-4-(piperidin-4-yl)pyrido[4′,3′...)
Affinity DataIC50:  13nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290309((−)-trans-10-Ethoxy-4-(2-methylpiperidin-4-y...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290320(10-Cyclopentyl-4-(piperidin-4-yl)pyrimido[1,2-b]in...)
Affinity DataIC50:  13nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290307((−)-trans-10-Bromo-4-(2-methylpiperidin-4-yl...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290329(10-sec-Butyl-4-(piperidin-4-yl)pyrimido[1,2-b]inda...)
Affinity DataIC50:  14nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290269(10-Bromo-4-(piperidin-4-yl)pyrimido[1,2-b]indazol-...)
Affinity DataIC50:  14nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290313(10-Phenyl-4-(piperidin-4-yl)pyrimido[1,2-b]indazol...)
Affinity DataIC50:  14nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290312(4-(Piperidin-4-yl)-10-[4-(trifluoromethyl)phenyl]p...)
Affinity DataIC50:  14nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290307((−)-trans-10-Bromo-4-(2-methylpiperidin-4-yl...)
Affinity DataIC50:  14nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290329(10-sec-Butyl-4-(piperidin-4-yl)pyrimido[1,2-b]inda...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 966 total ) | Next | Last >>
Jump to: